Trial results show significant faster time to clinical improvement with Favipiravir: Glenmark

Results from the Phase 3 trial showed numerical improvements for the
primary efficacy endpoint with 28.6 per cent faster viral clearance in
the overall population in the Favipiravir plus standard supportive
care compared to those in the standard supportive care alone (control
arm) , Glenmark said in a statement.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/trial-results-show-significant-faster-time-to-clinical-improvement-with-favipiravir-glenmark/articleshow/77110336.cms